CompanyCLDXNasdaqHampton, NJ

Celldex Therapeutics

Celldex develops antibody-based immunology therapies for allergic, inflammatory, and autoimmune disorders.

SEC EDGAR ClinicalTrials.gov celldex.com

8-KSep 22Latest SEC filing, period to Sep 22

Sep 22Latest story

September 2026

Celldex says barzolvolimab hit all primary and secondary goals in two Phase 3 CSU trials

Sep 22Clinical readoutbarzolvolimab Celldex Therapeutics

August 2026

Celldex reports Q2 2026 results as barzolvolimab Phase 3 enrollment finishes early

Aug 6Quarterly updatebarzolvolimab Celldex Therapeutics

July 2026

Celldex CFO Sam Martin to retire in March 2027

Jul 15PeopleCelldex Therapeutics